CARD8 and cancer: In our results, TMPO-AS1/miR-126-5p/SPP1 and CARD8-AS1/miR-21-5p/TEK are not only related to LUAD progression, but also function as immunotherapeutic targets for LUAD, clarifying a novel mechanism in cancer therapy.